Best in 7 days
Pay in installments of $5.70 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
Tirzepatide Injection: The Ultimate Guide for Diabetes and Obesity Management Bmi Doctors Thigh injection muscular : r tirzepatidecompound It's officially TIRZ day! Tirzepatide ODT is our new, orange flavored, injection free GLP 1 option for needle nervous patients. Go to the link in bio to find out more. #Tirzepatide #ODT #WeightManagement #EmpowerPharmacy #CompoundingisPersonal What Is Tirzepatide Used for? Approved and Potential Uses GoodRx
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
Discover Niche Categories That Outsell summit trial tirzepatide results
Top-Converting Item to Boost Your Average Order
Best in 7 days
Best in 7 days
Best in 7 days
Best in 7 days
4.5 ★★★★★
Based on 1945 reviews
Sort
Product Reviews
★★★★★ 5
Must Have Book for Investors or Sponsors/GPs wanting to Invest in Multifamily Properties!
Format: Paperback
If you understand the math and numbers associated with investing in real estate, this book will help you underwrite any multifamily property. Not only does Robert's book discuss how to gather the information needed for underwriting, he goes into detail on how sponsors can manipulate the numbers. This is a great book for knowledge on the pros and cons of varied partnership structures and how each can create an alignment of interest between limited partners (LPs) and general partners (GPs). Overall, this is a great easy read book.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on September 13, 2020
★★★★★ 4
Basic knowledge of underwriting is necessary to understand.
Format: Paperback
This is a great guide for underwriting multifamily deals for someone with some basic to moderate knowledge of underwriting. I am a new student to this field and have to stop and google some of the acronyms. For a future version, I think adding an extra page for the acronyms used, definition and equation would be helpful. I think that the font could be larger and darker. Adding mathematical formulas in the book would provide visualization as well. Rob can also provide a sample OM for the reader to use with his underwriting model and compare to his completed one. Again, I am a newbie so my review may change as I gain knowledge in this area. I enjoyed listening to Rob on Youtube/Podcast and hope to learn more from him.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on July 27, 2020
★★★★★ 5
Easy to understand and well organized
Format: Paperback
Author makes complex concepts feel approachable and easy to comprehend. The content is sufficient to be an introductory course
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on October 22, 2025
★★★★★ 5
great read for underwriters of multifamily deals
Format: Kindle
Rob lays out a succinct and thorough summary of his underwriting process, questions industry standards while sharing his opinions, and discusses risk management and analyses for deals during the underwriting process. Highly recommend for newer and more seasoned underwriters and investors to build or sharpen multifamily underwriting fundamentals and details. He also shares his model as the example.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on September 27, 2023
★★★★★ 3
Needs more meat
Format: Paperback
A little on the light side of information provided. Some nuggets. OK value.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on December 16, 2022
recommand products
Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction
22.74
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
25.30
3. Integration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD
24.40
kentucky glp-1 gastrointestinal obstruction class action GLP-1
22.56
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
25.41